 CARLSBAD, Calif., Sept. 12, 2022 GLOBE NEWSWIRE -- Pardes Biosciences, Inc. NASDAQ: PRDS, a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases i.e., COVID-19, today announced that management will participate in a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 7:30 a.m. PT 10:30 a.m. ET in New York City. 